2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups

Objective: To develop and validate new classification criteria for adult and juvenile idiopathic inflammatory myopathies (IIM) and their major subgroups.

Methods: Candidate variables were assembled from published criteria and expert opinion using consensus methodology. Data were collected from 47 rheumatology, dermatology, neurology, and pediatric clinics worldwide. Several statistical methods were utilized to derive the classification criteria.

Results: Based on data from 976 IIM patients (74% adults; 26% children) and 624 non-IIM patients with mimicking conditions (82% adults; 18% children), new criteria were derived. Each item is assigned a weighted score. The total score corresponds to a probability of having IIM. Subclassification is performed using a classification tree. A probability cutoff of 55%, corresponding to a score of 5.5 (6.7 with muscle biopsy) "probable IIM," had best sensitivity/specificity (87%/82% without biopsies, 93%/88% with biopsies) and is recommended as a minimum to classify a patient as having IIM. A probability of ≥90%, corresponding to a score of ≥7.5 (≥8.7 with muscle biopsy), corresponds to "definite IIM." A probability of <50%, corresponding to a score of <5.3 (<6.5 with muscle biopsy), rules out IIM, leaving a probability of ≥50-<55% as "possible IIM."

Conclusion: The European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria for IIM have been endorsed by international rheumatology, dermatology, neurology, and pediatric groups. They employ easily accessible and operationally defined elements, and have been partially validated. They allow classification of "definite," "probable," and "possible" IIM, in addition to the major subgroups of IIM, including juvenile IIM. They generally perform better than existing criteria.

Citing Articles

Alterations in nailfold videocapillaroscopy among patients with connective tissue diseases combined with pulmonary arterial hypertension: A cross-sectional study.

Tang Z, Yang F, Wu H, Zhao Y, Shen J, Hong H Sci Rep. 2025; 15(1):8647.

PMID: 40082520 PMC: 11906740. DOI: 10.1038/s41598-025-92093-7.

Plasma levels of adhesion molecules are elevated in dermatomyositis-interstitial lung disease and associated with low paraoxonase-1 activity.

Bae S, Shahbazian A, Wang J, Markovic D, De Leon T, Lee Y Arthritis Res Ther. 2025; 27(1):53.

PMID: 40055821 PMC: 11889823. DOI: 10.1186/s13075-025-03520-z.

Ultrasound Beyond Joints: A Review of Extra-Articular Applications in Rheumatology.

DIgnazio E, Corradini D, Cazenave T, Bixio R, Baldi C, Ubhi H Curr Rheumatol Rep. 2025; 27(1):20.

PMID: 40035992 PMC: 11880079. DOI: 10.1007/s11926-025-01186-9.

Ultrasensitive interferons quantification reveals different cytokine profile secretion in inflammatory myopathies and can serve as biomarkers of activity in dermatomyositis.

Bolko L, Anquetil C, Llibre A, Maillard S, Amelin D, Dorgham K Front Immunol. 2025; 16:1529582.

PMID: 40013143 PMC: 11861187. DOI: 10.3389/fimmu.2025.1529582.

Clinical features and survival analysis of 40 cases of anti-MDA5 antibody-positive dermatomyositis complicated with interstitial lung disease.

Zhao K, Zhang J, Kong Q, Zhang Y, Li C, Huo K Arthritis Res Ther. 2025; 27(1):32.

PMID: 39948593 PMC: 11823200. DOI: 10.1186/s13075-025-03485-z.

References

Bohan A, Peter J . Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975; 292(7):344-7. DOI: 10.1056/NEJM197502132920706. View

Plotz P, Rider L, Targoff I, Raben N, OHanlon T, Miller F . NIH conference. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy. Ann Intern Med. 1995; 122(9):715-24. DOI: 10.7326/0003-4819-122-9-199505010-00010. View

Dalakas M, Hohlfeld R . Polymyositis and dermatomyositis. Lancet. 2003; 362(9388):971-82. DOI: 10.1016/S0140-6736(03)14368-1. View

Hoogendijk J, Amato A, Lecky B, Choy E, Lundberg I, Rose M . 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord. 2004; 14(5):337-45. DOI: 10.1016/j.nmd.2004.02.006. View

Rider L, Nistala K . The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. J Intern Med. 2016; 280(1):24-38. PMC: 4914449. DOI: 10.1111/joim.12444. View

Griggs R, Askanas V, DiMauro S, Engel A, Karpati G, Mendell J . Inclusion body myositis and myopathies. Ann Neurol. 1995; 38(5):705-13. DOI: 10.1002/ana.410380504. View

Engel A, Arahata K . Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. Hum Pathol. 1986; 17(7):704-21. DOI: 10.1016/s0046-8177(86)80180-0. View

Ruperto N, Meiorin S, Iusan S, Ravelli A, Pistorio A, Martini A . Consensus procedures and their role in pediatric rheumatology. Curr Rheumatol Rep. 2008; 10(2):142-6. DOI: 10.1007/s11926-008-0025-6. View

van der Meulen M, Bronner I, Hoogendijk J, Burger H, van Venrooij W, Voskuyl A . Polymyositis: an overdiagnosed entity. Neurology. 2003; 61(3):316-21. DOI: 10.1212/wnl.61.3.316. View

10.

Dalakas M . Inflammatory muscle diseases. N Engl J Med. 2015; 372(18):1734-47. DOI: 10.1056/NEJMra1402225. View

11.

Medsger Jr T, Dawson Jr W, MASI A . The epidemiology of polymyositis. Am J Med. 1970; 48(6):715-23. DOI: 10.1016/s0002-9343(70)80006-7. View

12.

Troyanov Y, Targoff I, Tremblay J, Goulet J, Raymond Y, Senecal J . Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore). 2005; 84(4):231-249. DOI: 10.1097/01.md.0000173991.74008.b0. View

13.

Casciola-Rosen L, Mammen A . Myositis autoantibodies. Curr Opin Rheumatol. 2012; 24(6):602-8. PMC: 3874450. DOI: 10.1097/BOR.0b013e328358bd85. View

14.

Fett N, Liu R . Multicentric reticulohistiocytosis with dermatomyositis-like features: a more common disease presentation than previously thought. Dermatology. 2011; 222(2):102-8. DOI: 10.1159/000323254. View

15.

Rider L, Giannini E, Brunner H, Ruperto N, James-Newton L, Reed A . International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum. 2004; 50(7):2281-90. DOI: 10.1002/art.20349. View

16.

Miller F, Rider L, Plotz P, Rutkove S, Pestronk A, Wortmann R . Polymyositis: an overdiagnosed entity. Neurology. 2004; 63(2):402. View

17.

Betteridge Z, McHugh N . Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med. 2015; 280(1):8-23. DOI: 10.1111/joim.12451. View

18.

Aggarwal R, Ringold S, Khanna D, Neogi T, Johnson S, Miller A . Distinctions between diagnostic and classification criteria?. Arthritis Care Res (Hoboken). 2015; 67(7):891-7. PMC: 4482786. DOI: 10.1002/acr.22583. View

19.

Bradley W . Polymyositis: an overdiagnosed entity. Neurology. 2004; 63(2):402. View

20.

Dougados M, Gossec L . Classification criteria for rheumatic diseases: why and how?. Arthritis Rheum. 2007; 57(7):1112-5. DOI: 10.1002/art.23015. View